Supplemental Financial Information (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Inventories

The following table presents the components of inventories as of December 31, 2023 and 2022 (in thousands):

	2023		2022
Raw materials	$	81,878	$	70,027
Work-in-process	12,901		15,508
Finished goods	53,108		43,844
Total inventories	$	147,887	$	129,379

Schedule of Property, Plant and Equipment

The following table presents the components of property, plant and equipment, net as of December 31, 2023 and 2022 (in thousands):

	2023		2022		Lives in Years
Land	$	14,902	$	14,637
Building and building improvements	84,543		80,611		5	to	36
Equipment, software, furniture and fixtures	233,337		206,892		2	to	20
Other	6,690		8,861		5	to	10
Capital investment in process	10,745		11,307
Total gross property, plant and equipment	350,217		322,308
Accumulated depreciation	(196,036)		(175,121)
Total property, plant and equipment, net	$	154,181	$	147,187

Schedule of Accrued Liabilities

The following table presents the components of accrued liabilities and other as of December 31, 2023 and 2022 (in thousands):

	2023		2022
Legal and professional costs	$	17,794	$	8,653
Contingent consideration	13,750		—
Contract liabilities	10,725		10,226
Operating lease liabilities (1)	8,362		9,379
Italian medical device payback law	8,223		6,414
Interest payable	7,840		(76)
Royalty accrual	4,441		3,950
Current derivative liabilities	3,883		5,886
Provisions for agents, returns and other	4,464		1,678
Research and development costs	2,462		7,020
Restructuring liabilities (2)	911		2,045
Other accrued expenses	24,446		26,306
Total accrued liabilities and other	$	107,301	$	81,481

(1)Refer to “Note 12. Leases.”

(2)Refer to “Note 6. Restructuring.”

Schedule of Foreign Exchange and Other Gains/(Losses)

The following table presents the items included within foreign exchange and other income/(expense) on the consolidated statements of income (loss) for the years ended December 31, 2023, 2022 and 2021 (in thousands):

	2023		2022		2021
Notes fair value adjustment (1)	$	40,106	$	96,025	$	(59,944)
Capped call fair value adjustment (1)	(15,897)		(52,236)		34,327
Interest income	22,012		4,697		435
Foreign exchange rate fluctuations	(705)		378		(1,243)
Dividend income	1,540		305		3,415
Investment revaluation	—		—		4,642
Other derivative liabilities fair value adjustment	—		—		4,290
Other	(931)		691		779
Total foreign exchange and other income/(expense)	$	46,125	$	49,860	$	(13,299)

(1)Refer to “Note 9. Fair Value Measurements.”

Restrictions on Cash and Cash Equivalents

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to the total of the amounts shown on the consolidated statements of cash flows as of December 31, 2023 and 2022 (in thousands):

	2023		2022
Cash and cash equivalents	$	266,504	$	214,172
Restricted cash (1)	311,368		301,446
Cash, cash equivalents and restricted cash	$	577,872	$	515,618

(1)Restricted cash represents funds held as collateral for the SNIA Litigation Guarantee. Refer to “Note 13. Commitments and Contingencies.”

Schedule of Cash and Cash Equivalents

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to the total of the amounts shown on the consolidated statements of cash flows as of December 31, 2023 and 2022 (in thousands):

	2023		2022
Cash and cash equivalents	$	266,504	$	214,172
Restricted cash (1)	311,368		301,446
Cash, cash equivalents and restricted cash	$	577,872	$	515,618

(1)Restricted cash represents funds held as collateral for the SNIA Litigation Guarantee. Refer to “Note 13. Commitments and Contingencies.”